Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

ArQule

Spark Therapeutics

Roche Holding AG

Sanofi

Synthorx Inc

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

ArQule stock rocketed more than 100% early Monday after Dow Jones stock Merck pledged to buy it for $2.7 billion. The biotech company is working on precision medicine in cancer treatment.

This Biotech Stock Rocketed 103% On Merck's $2.7 Billion Takeover

Merck (NYSE: MRK) will acquire ArQule, Inc. (NASDAQ: ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion.

ArQule To Be Acquired By Merck For $2.7B

Merck said on Monday it would buy cancer drug developer ArQule in a $2.7 billion all-cash deal, bolstering its oncology franchise with the smaller rival's lead drug that is being tested as a treatment for blood cancer.

Merck to buy cancer drug developer ArQule for $2.7 billion in cash

Merck & Co. Inc. MRK, +0.11% said Monday it has entered an agreement to acquire ArQule Inc.

Merck to acquire ArQule for $20 per share in cash or about $2.7 billion

Anthem

Johnson & Johnson

UnitedHealth Group

According to the Aggregated Portfolio, a GuruFocus Premium feature, the four broadest-owned stocks within the health care sector are UnitedHealth Group Inc.

4 Health Care Stocks Gurus Broadly Own

Merck stock is on an upswing with a 14% gain in the first 11 full months of 2019. Meanwhile shares of other pharma companies grabbed a smaller gain.

Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?

Merck's key growth driver may just be getting started.

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Seagen

Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.

Seattle Genetics, Astellas Tie Up With Merck for Cancer Study

Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.

Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer

Bristol-Myers

GlaxoSmithKline

Pfizer

Large-Cap Pharmaceuticals Industry Prospects Bright for 2020

AbbVie

Allergan

Jazz Pharmaceuticals

Zoetis

Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

American Express

Intel

Coca-Cola

NIKE

Dow Jones stocks Merck, Nike, Intel, American Express and Coca-Cola are just below buy points as the market looks toward a Santa Claus rally.
The post Dow Jones Stocks Merck, Intel, American Express, Coca-Cola, Nike Are Near Buy Points appeared first on Investor's Business Daily.

Dow Jones Stocks Merck, Intel, American Express, Coca-Cola, Nike Are Near Buy Points

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 1.6% Since Last Earnings Report?

Merck's (MRK) shares are up 11.7% this year so far on strong performance and positive regulatory updates on its PD-1 inhibitor Keytruda.

Here's Why Merck's (MRK) Shares Are Up This Year

Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.

Merck's Keytruda Gets Nod in China for Difficult Lung Cancer

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Hike Their Bets

Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.

Merck (MRK) is an Incredible Growth Stock: 3 Reasons Why

Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.

Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer

Walmart

We’ve got your market gloom for Wednesday.

Need to Know: Your three-stock survival kit for 2020, says this equity strategist

Shares of Merck & Co. Inc. MRK, +0.27% were up 0.3% in midday trading Tuesday, after the health care company said it will raise its quarterly dividend by 11%.

Merck raises quarterly dividend, to yield more than peers and the S&P 500

Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.

Merck's Heart Failure Candidate Meets Goal in Phase III Study

Microsoft

Procter & Gamble

We highlight blue-chip companies slated to gain in the near term as they have large market capitalization, strong balance sheet and solid cash flow.

5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000

Drug stocks have been out of favor due to regulatory concerns. Nevertheless, several top-tier stock experts and contributors to MoneyShow.com see select opportunities for long-term value investors to consider buying large cap pharmaceutical names.

Out-of-Favor Drugs Stocks May be the Right Medicine For Your Portfolio

AstraZeneca

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

News for Merck Stock (MRK)